Patents Assigned to Medarex, L.L.C.
  • Patent number: 9062111
    Abstract: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 23, 2015
    Assignee: MEDAREX, L.L.C.
    Inventors: Geoffrey M. Nichol, Israel Lowy
  • Publication number: 20150165025
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: November 18, 2014
    Publication date: June 18, 2015
    Applicants: Medarex, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. KORMAN, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Patent number: 8981071
    Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: March 17, 2015
    Assignees: Amgen, Inc., Medarex, L.L.C.
    Inventors: Gerald Siu, Wenyan Shen, Steven K. Yoshinaga, Haichun Huang
  • Patent number: 8945546
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: February 3, 2015
    Assignee: Medarex, L.L.C.
    Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
  • Publication number: 20140335099
    Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
    Type: Application
    Filed: March 5, 2014
    Publication date: November 13, 2014
    Applicants: Amgen Inc., Medarex, L.L.C.
    Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
  • Publication number: 20140328833
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: May 6, 2014
    Publication date: November 6, 2014
    Applicants: Medarex, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Patent number: 8865875
    Abstract: The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: October 21, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Jie Liu, David King
  • Patent number: 8835712
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: September 16, 2014
    Assignees: Medarex, L.L.C., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Patent number: 8828393
    Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: September 9, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King
  • Publication number: 20140234331
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: Medarex, L.L.C.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Patent number: 8802632
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: August 12, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong
  • Patent number: 8784815
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: July 22, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Patent number: 8779105
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: July 15, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bing Chen, Josephine M. Cardarelli, Haichun Huang
  • Patent number: 8772543
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: July 8, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong, Qian Zhang
  • Patent number: 8772542
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: July 8, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong
  • Patent number: 8765415
    Abstract: The present invention provides a method of increasing protein production in a cell culture by growing cells that produce the protein (e.g., the growth phase) in a perfusion cell culture to a high cell density (i.e., at least above about 40×106 cells/N mL) and then switching to a protein production phase, wherein the cells are cultured in a fed-batch cell culture. The present invention further provides a method for clarifying a protein from a cell culture by adjusting the pH of the cell culture to below neutral pH (i.e., below a pH of 7) and settling the cell culture, such that the cell culture separates to form a supernatant layer and a cell-bed layer, wherein the protein is in the supernatant layer.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: July 1, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Alahari Arunakumari, Xiao-Ping Dai, Javier Garcia, Richard P. Martel
  • Publication number: 20140179904
    Abstract: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Medarex, L.L.C.
    Inventors: Alahari Arunakumari, Gisela Maria Marques Ferreira
  • Patent number: 8758757
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: June 24, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Publication number: 20140134180
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.
    Type: Application
    Filed: November 7, 2013
    Publication date: May 15, 2014
    Applicant: MEDAREX, L.L.C.
    Inventors: ALAN J. KORMAN, MARK J. SELBY, LI-SHENG LU, ALISON J. WITTE, HAICHUN HUANG
  • Patent number: 8722870
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: May 13, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Alison J. Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore